TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma

Along with tumor progression, the bone marrow microenvironment is skewed in multiple myeloma (MM), which underlies the unique pathophysiology of MM and confers aggressiveness and drug resistance in MM cells. TGF-b-activated kinase-1 (TAK1) mediates a wide range of intracellular signaling pathways. W...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Teramachi, Jumpei, Tenshin, Hirofumi, Hiasa, Masahiro, Oda, Asuka, Bat-Erdene, Ariunzaya, Harada, Takeshi, Nakamura, Shingen, Ashtar, Mohannad, Shimizu, So, Iwasa, Masami, Sogabe, Kimiko, Oura, Masahiro, Fujii, Shiro, Kagawa, Kumiko, Miki, Hirokazu, Endo, Itsuro, Haneji, Tatsuji, Matsumoto, Toshio, Abe, Masahiro
Format: Artigo
Idioma:Inglês
Publicat: Fondazione Ferrata Storti 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094086/
https://ncbi.nlm.nih.gov/pubmed/32273474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.234476
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars